Potent, selective, covalent inhibitors of IDH-1 (LY3410738) are also being studied in advanced cholangiocarcinoma by Pauff et al. [34]. This phase I study with a dose-escalation cohort has a primary objective of determining the maximum tolerated dose when administered alone or with the current standard of care. The authors state that this inhibitor binds uniquely to the mutant enzyme, increasing its potency and enabling activity in second-site mutation points. The gene discussed is IDH1; the disease is cholangiocarcinoma.